Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

short-term repeated dose toxicity: oral
Type of information:
migrated information: read-across based on grouping of substances (category approach)
Adequacy of study:
key study
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: guideline study

Data source

Reference Type:
study report
Report date:

Materials and methods

Test guideline
according to guideline
OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
GLP compliance:
yes (incl. QA statement)
Limit test:

Test material

Constituent 1
Reference substance name:
2,2',2''-Nitrilotriethanol, propoxylated
EC Number:
EC Name:
2,2',2''-Nitrilotriethanol, propoxylated
Details on test material:
- Name of test material (as cited in study report): Polyether V 579
- Molecular weight (if other than submission substance): (Mm = approx. 340 g/mol)

- Physical state: liquid
- Content: > 99% (test material is a mixture of oligomers which comprises more than 99% of the test substance and is formed by a polyaddition reaction between 2,2',2''-Nitrilotriethanol, propoxylated and 3.2 molar equivalents propyleneoxide.)

Test animals


Administration / exposure

Route of administration:
oral: gavage
Details on oral exposure:
- Amount of vehicle (if gavage): 5 ml/kg bw
Analytical verification of doses or concentrations:
Details on analytical verification of doses or concentrations:
The content of the test item was assumed to be nominally 100% for calculation.
Before the start of the study formulations containing the test item in concentrations
of 2 mg/mI and 200 mg/ml were analyzed to determine homogeneous distribution
(not for the 2mg/ml formulation as it was a solution), content and stability of the test
item in tap water. During the study homogeneity and content was checked twice.
Duration of treatment / exposure:
31 days
Frequency of treatment:
once daily
Doses / concentrations
Doses / Concentrations:
100, 300 and 1000 mg/kg bw
actual ingested
No. of animals per sex per dose:
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale:
The dose levels used were based on the results of a pilot study. During this study Wistar rats (2 males and 2 females per dose group) received the test substance in doses of O, 65, 160, 400, 1000 mg/kg for a period of two weeks. No clinical findings or relevant effects on body weight development were observed in this study.

Positive control:
no positive control


Observations and examinations performed and frequency:
- Time schedule: daily

DETAILED CLINICAL OBSERVATIONS: Yes (incl. Open Field Observations (OFO))
- Time schedule: day 8, 15, 22, 28

- Time schedule for examinations: daily

- Time schedule for examinations: weekly


- Time schedule for collection of blood: once, day 30
- How many animals: all dose groups incl. controls

- Time schedule for collection of blood: once, day 30
- How many animals: all dose groups incl. controls


- Time schedule for examinations: FOB: once, day 25; MA: once, day 29
- Dose groups that were examined: all dose groups incl. controls
- Battery of functions tested: Functional Observational Battery (FOB); Motor Activity (MA)
Sacrifice and pathology:
GROSS PATHOLOGY: Yes (all dose groups and controls)

ORGAN Weights:
Adrenals, brain, epididymides, heart, kidneys, Liver, Ovaries, Spleen, Testes, Thymus, uterus

Fixed organs:
Adrenals, aorta, brain (cerebrum, cerebellum, ponslmedulla), epididymides, esophagus, eyes, eyelids, extraorbital lachrymal glands, femur, harderian glands, head (with nasal and paranasal cavities), heart, intestine (duodenum, jejunum, ileum, cecum, colon, rectum and remaining intestine), kidneys, larynx, liver, lymph nodes (mandibular, bronchial/hilus, and mesenteric), lung, mamma, optical nerves, ovaries, oviducts, pancreas, pharynx, pituitary, prostate, salivary glands, sciatic nerve, seminal vesicles (incl. coagulating glands), skeletal muscle (thigh), skin (mammary and muzzle), spinal cord (cervical, thoracic, lumbar), spleen, sternum, stomach (forestomach and glandular stomach), testes, thymus, thyroids (including parathyroid glands), tongue, trachea, ureter, urethra, urinary bladder, uterus with uterine cervix, vagina, Zymbal’s glands and all organs or tissues with macroscopic findings.

HISTOPATHOLOGY: Yes (high dose group and controls)
- Microscopic: Adrenals, brain (cerebrum, cerebellum, ponslmedulla), epididymides, femur, heart, intestine (duodenum, jejunum, ileum, cecum, colon, rectum and remaining intestine), kidneys, liver, lung, lymph nodes, ovaries, oviducts, pancreas, pituitary, prostate, salivary glands, sciatic nerve, seminal vesicles (incl. coagulating glands), skeletal muscle (thigh), skin (mammary and muzzle), spinal cord (cervical, thoracic, lumbar), spleen, sternum, stomach (forestomach and glandular stomach), testes, thymus, thyroids (including parathyroid glands), trachea, urinary bladder, uterus with uterine cervix, and all organs or tissues with macroscopic findings. Slides were prepared from the first five animals of all groups and evaluated from the control and the high concentration group.

Results and discussion

Results of examinations

Clinical signs:
no effects observed
no mortality observed
Body weight and weight changes:
no effects observed
Food consumption and compound intake (if feeding study):
no effects observed
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
effects observed, treatment-related
Clinical biochemistry findings:
effects observed, treatment-related
Urinalysis findings:
not examined
Behaviour (functional findings):
no effects observed
Organ weight findings including organ / body weight ratios:
no effects observed
Gross pathological findings:
no effects observed
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Histopathological findings: neoplastic:
no effects observed
Details on results:

Differential blood count revealed as the only conspicuous finding, that the number of leucocytes and lymphocytes was highest in high dose males but was lowest in high dose females. However, these differences were slight compared to the differences between the means of historical control values and the upper 2 s-range in males and the lower 2s-range in females, respectively. Furthernore, the deviations from control value were in opposite directions in males and females and histopathological examinations revealed no corresponding findings. For these
reasons a toxicological relevance was not inferred from these data.

Clinical chemistry:
Clinical aboratory tests revealed a significantly increased activity of alanine aminotransferase in females at 1000 mg/kg. However, the difference to control was relatively slight and histopathological examination of the liver produced no evidence for a treatment-related effect. Therefore, a toxicological relevance is not assumed. Determination of substrates showed the plasma creatinine concentration in males at 1000 mg/kg to be significantly decreased and in all treated female groups to be significantly increased. However, the differences to the respective control value were slight, no dose dependence was present in females, the deviation from the respective control group pointed in opposite directions in males and females and histopathological examination of kidneys produced no corresponding finding. On the basis of these results this was was not considered to be of toxicological relevance.

The histopathological evaluation revealed a slightly more pronounced hypertrophy of the follicular cell epithelium in the thyroid gland of fernales ofthe high dose, in which not only centrally located follicles appeared hypertrophic but also follicles of the periphery. Hypertrophy was observed to a minimal degree also in females of the other dose groups including one control animal. Due to the slightly increased severity grade in females ofthe high dose group, an effect of the test substance cannot be completely ruled out. Such minimal changes are regarded to be caused by substances that interfere with general metabolic processes and are so far assessed as indirect and adaptive effects. If at all the findings in the present study were related to the treatment, they are therefore not considered as a primary adverse effect on thyroids. However, due to the missing dose response (incidence for follicular cell hypertrophy was: 1 /3/ 1 /3) and the lack of any other treatment-related changes a spontaneous occurrence e.g. by a general variability seems more likely.

Effect levels

Dose descriptor:
Effect level:
>= 1 000 mg/kg bw/day (actual dose received)
Basis for effect level:
other: no adverse effects noted up to the limit dose

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion

The NOAEL for the given test substance was 1000 mg/kg bw/day.
Executive summary:

In a repeated dose oral toxicity study in rats (Wistar, OECD TG 407), 2,2',2" -Nitrilotriethanol, propoxylated was adiministered via gavage to 5 rats/sex/dose at 0, 100, 300, 1000 mg/kg bw for 4 weeks.. No death was observed in either sex. No clinical effects were observed in both sex of all dose groups.There was no effect observed upon haematological, clinical biochemistry or macroscopic examination at any dose. Based on these results the NOAEL was considered to be 1000 mg/kg bw/day. If at all the slight changes in thyroids of females at 1000 mg/kg were related to the treatment, they are regarded as an indirect and adaptive effect.